Shares of Aemetis, Inc. (NASDAQ:AMTX – Get Free Report) have earned an average rating of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $12.95.
A number of research firms have recently issued reports on AMTX. HC Wainwright reissued a “buy” rating and issued a $28.00 price target on shares of Aemetis in a research note on Monday, December 23rd. StockNews.com raised shares of Aemetis to a “sell” rating in a research note on Friday, January 3rd.
View Our Latest Analysis on Aemetis
Institutional Investors Weigh In On Aemetis
Aemetis Price Performance
Shares of AMTX stock opened at $2.87 on Monday. The firm’s 50-day moving average is $3.28 and its two-hundred day moving average is $2.97. Aemetis has a 12 month low of $2.10 and a 12 month high of $7.03. The company has a market capitalization of $142.74 million, a PE ratio of -1.27 and a beta of 1.47.
Aemetis (NASDAQ:AMTX – Get Free Report) last issued its earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.09. The firm had revenue of $81.44 million for the quarter, compared to analysts’ expectations of $77.79 million. During the same period last year, the firm earned ($0.59) earnings per share. Sell-side analysts forecast that Aemetis will post -2.02 EPS for the current year.
Aemetis Company Profile
Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.
See Also
- Five stocks we like better than Aemetis
- What Investors Need to Know About Upcoming IPOs
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Health Care Stocks Explained: Why You Might Want to Invest
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Expert Stock Trading Psychology Tips
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.